Savara Inc. (SVRA)

Name: Savara Inc. (SVRA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Savara Inc. (SVRA)

Stock Card

$5.35

$-0.04 (-0.74%)

As on 01-Sep-2026 16:25EDT

Market cap

$1,081 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

7.9

Div. Yield

0 %

Savara (SVRA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 5.29 High: 5.41

52 Week Range

Low: 3.21 High: 7.01

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-4.8
Debt to Equity

0
Book Value

$--
EPS

$-0.6
Face value

--
Shares outstanding

205,460,015

10 Years Aggregate

CFO

$-344.13 Mln

EBITDA

$-344.91 Mln

Net Profit

$-465.84 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Savara (SVRA)	-11.3	-2.0	2.9	63.1	13.9	28.1	-16.0
BSE Sensex^*	-9.8	-2.2	2.8	-5.0	5.3	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 01-Sep-2026 | *As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Savara (SVRA)	96.4	-34.5	203.2	25.0	7.8	-74.3	-40.8
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Savara (SVRA)	5.4	1,080.7	0.0	-139.3	--	-80.3	--	7.9
Arrowhead Pharmaceuticals (ARWR)	82.7	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	260.3	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	71.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.9	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	107.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	363.8	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	538.7	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	583.2	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	353.4	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Savara (SVRA)

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3... development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania. Read more

Chairman & CEO

Mr. Matthew Pauls J.D., M.B.A.
Chairman & CEO

Mr. Matthew Pauls J.D., M.B.A.
Headquarters

Yardley, PA
Website

https://www.savarapharma.com

FAQs for Savara (SVRA)

What is the current share price of Savara Inc (SVRA) Today?

The share price of Savara Inc (SVRA) is $5.35 (NASDAQ) as of 01-Sep-2026 16:25 EDT. Savara Inc (SVRA) has given a return of 13.91% in the last 3 years.

What is the current PB & PE ratio of Savara Inc (SVRA)?

Since, TTM earnings of Savara Inc (SVRA) is negative, P/E ratio is not available.
The P/B ratio of Savara Inc (SVRA) is 7.85 times as on 28-Aug-2026, a 52 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.